Zhao, Sizheng StevenHarrison, Stephanie RChan, AntoniClarke, NickDavis, CharlotteEddison, JoeGregory, William JJones, Gareth TMarzo-Ortega, HelenaMurphy, Daniel JSandhu, VirinderjitSengupta, RajSiebert, StefanThompson, BenWebb, DaleYates, MaxGaffney, Karl2023-06-142023-06-142023-05-15Zhao, S S, Harrison, S R, Chan, A, Clarke, N, Davis, C, Eddison, J, Gregory, W J, Jones, G T, Marzo-Ortega, H, Murphy, D J, Sandhu, V, Sengupta, R, Siebert, S, Thompson, B, Webb, D, Yates, M & Gaffney, K 2023, 'Treatment of axial spondyloarthritis with biologic and targeted synthetic DMARDs : British Society for Rheumatology guideline scope', Rheumatology advances in practice, vol. 7, no. 2, rkad039. https://doi.org/10.1093/rap/rkad0392514-1775PubMedCentral: PMC10183299ORCID: /0000-0003-0016-7591/work/137297670https://hdl.handle.net/2164/20876Funding: This work was supported by the British Society for Rheumatology. Acknowledgements: S.S.Z. is supported by a National Institute for Health Research (NIHR) Clinical Lectureship and works in centres supported by Versus Arthritis (grant numbers 21173, 21754 and 21755). H.M.-O. is Chair and Trustee of the British Society for Spondyloarthritis (BRITSpA). H.M.-O. is supported by the NIHR Leeds Biomedical Research Centre (LBRC). The views expressed are those of the authors and not necessarily those of the (UK) National Health Service (NHS), the NIHR or the (UK) Department of Health. © The Author(s) 2023. Published by Oxford University Press on behalf of the British Society for Rheumatology.2388521engAxial spondyloarthritisASBiologicBiosimilarIL17JAK inhibitortreat-to-targetswitchingtaperingR MedicineRJournal item10.1093/rap/rkad03972